Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.

Mathias AA, West S, Hui J, Kearney BP.

Clin Pharmacol Ther. 2009 Jan;85(1):64-70. doi: 10.1038/clpt.2008.168. Epub 2008 Sep 24.

PMID:
18815591
2.

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Zeldin RK, Petruschke RA.

J Antimicrob Chemother. 2004 Jan;53(1):4-9. Epub 2003 Dec 4. Review.

PMID:
14657084
3.

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.

Hsu A, Granneman GR, Bertz RJ.

Clin Pharmacokinet. 1998 Oct;35(4):275-91. Review. Erratum in: Clin Pharmacokinet 1998 Dec;35(6):473.

PMID:
9812178
4.

Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.

Ramanathan S, Mathias AA, German P, Kearney BP.

Clin Pharmacokinet. 2011 Apr;50(4):229-44. doi: 10.2165/11584570-000000000-00000. Review.

PMID:
21348537
5.

Pharmacoenhancement of protease inhibitors.

Motwani B, Khayr W.

Am J Ther. 2006 Jan-Feb;13(1):57-63. Review.

PMID:
16428923
6.

Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.

Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI.

J Clin Psychopharmacol. 1999 Aug;19(4):293-6. Review. No abstract available.

PMID:
10440454
7.

Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.

Nguyen T, McNicholl I, Custodio JM, Szwarcberg J, Piontkowsky D.

AIDS Rev. 2016 Apr-Jun;18(2):101-11. Review.

PMID:
27196356
8.

Pharmacokinetic enhancers in HIV therapeutics.

Larson KB, Wang K, Delille C, Otofokun I, Acosta EP.

Clin Pharmacokinet. 2014 Oct;53(10):865-72. doi: 10.1007/s40262-014-0167-9. Review.

PMID:
25164142
9.

Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature.

Foisy MM, Yakiwchuk EM, Chiu I, Singh AE.

HIV Med. 2008 Jul;9(6):389-96. doi: 10.1111/j.1468-1293.2008.00579.x. Epub 2008 May 4. Review.

10.

Integrase inhibitors: a clinical review of raltegravir and elvitegravir.

Grant P, Zolopa A.

J HIV Ther. 2008 Jun;13(2):36-9. Review. No abstract available.

PMID:
18953272
11.

Gender: a possible determinant in dosing of dermatologic drugs--an overview.

Modjtahedi BS, Modjtahedi SP, Maibach HI.

Cutan Ocul Toxicol. 2006;25(3):195-210. Review.

PMID:
16980245
12.

Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs.

Greenblatt DJ, von Moltke LL.

J Clin Pharmacol. 2008 Nov;48(11):1350-5. doi: 10.1177/0091270008323754. Epub 2008 Aug 29. Review.

PMID:
18757784
13.
14.
16.

Factors impacting the delivery of therapeutic levels of pyrone-based HIV protease inhibitors.

Padbury GE, Zipp GL, Schwende FJ, Zhao Z, Koeplinger KA, Chong KT, Raub TJ, Thaisrivongs S.

Pharm Biotechnol. 1998;11:211-32. Review. No abstract available.

PMID:
9760682
17.

[Anesthetics and their drug interactions].

Ochiai R.

Masui. 2001 Dec;50 Suppl:S56-70. Review. Japanese. No abstract available.

PMID:
11871105
18.

[The influence of low intensive chemical loads on homeostasis and the problems of prophylaxis].

Litvinov NN.

Vopr Pitan. 2004;73(2):37-9. Review. Russian.

PMID:
15154372

Supplemental Content

Support Center